肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

肾癌分子靶向药物——阿昔替尼用药安全共识

2020-11-30 中国医促会泌尿健康促进分会 现代泌尿外科杂志.2020.25(11):958-963.

肾癌分子靶向药物

综合阿昔替尼上市7年来临床研究结果及真实世界经验，本共识旨在对以下几方面的问题进行详细介绍：如何正确地选择阿昔替尼靶向治疗的适应证；如何制订患者个体化的药物使用剂量及疗程；如何预防或处理药物不良反应；

中文标题：

肾癌分子靶向药物——阿昔替尼用药安全共识

发布机构：

中国医促会泌尿健康促进分会

发布日期：

2020-11-30

简要介绍：

综合阿昔替尼上市7年来临床研究结果及真实世界经验，本共识旨在对以下几方面的问题进行详细介绍：如何正确地选择阿昔替尼靶向治疗的适应证；如何制订患者个体化的药物使用剂量及疗程；如何预防或处理药物不良反应；如何推荐新辅助及辅助治疗，如何进行联合治疗；如何对患者进行随访等。总之，基于安全有效的使用阿昔替尼，本共识将从适应证、具体治疗方案实施、不良反应管理等方面进行介绍。

 

评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=970256, encodeId=a17c9e0256dd, content=赚积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210519/dda68257c8ca496c815c152543da32f1/2f4ca13ce0d2497ebe345afdf19d00b9.jpg, createdBy=6e9b2422578, createdName=brightAce, createdTime=Wed Jun 02 09:11:52 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964057, encodeId=e32e96405eba, content=赚积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210428/62bd4c426c19405fbe25daed5e303e21/325bee3412d648c38717826432a9bc53.jpg, createdBy=f0305306362, createdName=忻雨, createdTime=Sun May 09 19:07:09 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963840, encodeId=c97b9638407b, content=了解咯, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210428/62bd4c426c19405fbe25daed5e303e21/325bee3412d648c38717826432a9bc53.jpg, createdBy=f0305306362, createdName=忻雨, createdTime=Sun May 09 00:07:43 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911401, encodeId=933991140172, content=肾癌分子靶向药物——阿昔替尼用药安全共识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Dec 27 21:07:22 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=910354, encodeId=d6ed91035434, content=该药物靶向的分子靶标是什么？谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c445116369, createdName=ms2000002142302605, createdTime=Wed Dec 23 14:25:18 CST 2020, time=2020-12-23, status=1, ipAttribution=)]
    2021-06-02 brightAce

    赚积分

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=970256, encodeId=a17c9e0256dd, content=赚积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210519/dda68257c8ca496c815c152543da32f1/2f4ca13ce0d2497ebe345afdf19d00b9.jpg, createdBy=6e9b2422578, createdName=brightAce, createdTime=Wed Jun 02 09:11:52 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964057, encodeId=e32e96405eba, content=赚积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210428/62bd4c426c19405fbe25daed5e303e21/325bee3412d648c38717826432a9bc53.jpg, createdBy=f0305306362, createdName=忻雨, createdTime=Sun May 09 19:07:09 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963840, encodeId=c97b9638407b, content=了解咯, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210428/62bd4c426c19405fbe25daed5e303e21/325bee3412d648c38717826432a9bc53.jpg, createdBy=f0305306362, createdName=忻雨, createdTime=Sun May 09 00:07:43 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911401, encodeId=933991140172, content=肾癌分子靶向药物——阿昔替尼用药安全共识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Dec 27 21:07:22 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=910354, encodeId=d6ed91035434, content=该药物靶向的分子靶标是什么？谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c445116369, createdName=ms2000002142302605, createdTime=Wed Dec 23 14:25:18 CST 2020, time=2020-12-23, status=1, ipAttribution=)]
    2021-05-09 忻雨

    赚积分

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=970256, encodeId=a17c9e0256dd, content=赚积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210519/dda68257c8ca496c815c152543da32f1/2f4ca13ce0d2497ebe345afdf19d00b9.jpg, createdBy=6e9b2422578, createdName=brightAce, createdTime=Wed Jun 02 09:11:52 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964057, encodeId=e32e96405eba, content=赚积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210428/62bd4c426c19405fbe25daed5e303e21/325bee3412d648c38717826432a9bc53.jpg, createdBy=f0305306362, createdName=忻雨, createdTime=Sun May 09 19:07:09 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963840, encodeId=c97b9638407b, content=了解咯, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210428/62bd4c426c19405fbe25daed5e303e21/325bee3412d648c38717826432a9bc53.jpg, createdBy=f0305306362, createdName=忻雨, createdTime=Sun May 09 00:07:43 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911401, encodeId=933991140172, content=肾癌分子靶向药物——阿昔替尼用药安全共识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Dec 27 21:07:22 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=910354, encodeId=d6ed91035434, content=该药物靶向的分子靶标是什么？谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c445116369, createdName=ms2000002142302605, createdTime=Wed Dec 23 14:25:18 CST 2020, time=2020-12-23, status=1, ipAttribution=)]
    2021-05-09 忻雨

    了解咯

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=970256, encodeId=a17c9e0256dd, content=赚积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210519/dda68257c8ca496c815c152543da32f1/2f4ca13ce0d2497ebe345afdf19d00b9.jpg, createdBy=6e9b2422578, createdName=brightAce, createdTime=Wed Jun 02 09:11:52 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964057, encodeId=e32e96405eba, content=赚积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210428/62bd4c426c19405fbe25daed5e303e21/325bee3412d648c38717826432a9bc53.jpg, createdBy=f0305306362, createdName=忻雨, createdTime=Sun May 09 19:07:09 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963840, encodeId=c97b9638407b, content=了解咯, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210428/62bd4c426c19405fbe25daed5e303e21/325bee3412d648c38717826432a9bc53.jpg, createdBy=f0305306362, createdName=忻雨, createdTime=Sun May 09 00:07:43 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911401, encodeId=933991140172, content=肾癌分子靶向药物——阿昔替尼用药安全共识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Dec 27 21:07:22 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=910354, encodeId=d6ed91035434, content=该药物靶向的分子靶标是什么？谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c445116369, createdName=ms2000002142302605, createdTime=Wed Dec 23 14:25:18 CST 2020, time=2020-12-23, status=1, ipAttribution=)]
    2020-12-27 oo902

    肾癌分子靶向药物——阿昔替尼用药安全共识

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=970256, encodeId=a17c9e0256dd, content=赚积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210519/dda68257c8ca496c815c152543da32f1/2f4ca13ce0d2497ebe345afdf19d00b9.jpg, createdBy=6e9b2422578, createdName=brightAce, createdTime=Wed Jun 02 09:11:52 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964057, encodeId=e32e96405eba, content=赚积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210428/62bd4c426c19405fbe25daed5e303e21/325bee3412d648c38717826432a9bc53.jpg, createdBy=f0305306362, createdName=忻雨, createdTime=Sun May 09 19:07:09 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963840, encodeId=c97b9638407b, content=了解咯, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210428/62bd4c426c19405fbe25daed5e303e21/325bee3412d648c38717826432a9bc53.jpg, createdBy=f0305306362, createdName=忻雨, createdTime=Sun May 09 00:07:43 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911401, encodeId=933991140172, content=肾癌分子靶向药物——阿昔替尼用药安全共识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Dec 27 21:07:22 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=910354, encodeId=d6ed91035434, content=该药物靶向的分子靶标是什么？谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c445116369, createdName=ms2000002142302605, createdTime=Wed Dec 23 14:25:18 CST 2020, time=2020-12-23, status=1, ipAttribution=)]
    2020-12-23 ms2000002142302605

    该药物靶向的分子靶标是什么？谢谢

    0

相关指南

肾癌分子靶向药舒尼替尼用药安全共识

中国医促会泌尿健康促进分会 · 2020-10-20

2020年欧洲泌尿协会肾癌诊断和治疗指南概要

暂未更新 · 2020-10-20

肾癌骨转移专家共识（2020 版）

暂未更新 · 2020-07-30

2019 KCRNC共识声明：肾肿块活检在肾癌管理中的作用

加拿大肾脏肿瘤研究网络(KCRNC,Kidney Cancer Research Network of Canada) · 2019-12-13

肾癌靶向药物治疗安全共识

中国医促会泌尿健康促进分会 · 2019-10-30

肾癌诊疗规范（2018年版）

中华人民共和国国家卫生健康委员会 · 2018-12-13